CX-904 showcased a favorable safety profile, a critical factor in the administration and monitoring of patients in outpatient settings. CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...
71756907 :
From what i’ve learned its their dilution that may have caused the fall, they had certain limits of share price where they were granted additional funding of three levels which where hit in the after hours of the report. This may have spooled the investors.
Pioneering a New Era in Cancer Treatment: CytomX and Merck's Strategic Collaboration on CX-801. Striding towards revolutionizing cancer therapy, CytomX Therapeutics, Inc. (Nasdaq: CTMX) has announced a clinical trial collaboration and supply agreement with pharmaceutical giant Merck (known as MSD outside of the US and Canada). This collaboration is set to explore the therapeutic potential of CX-801, a novel, dually-m...
Trytosaveabitスレ主PaulG:
Yup! But it was a great scalp! Well if you trade like that! I don’t think it’s going to fully recover until people are sure whether another 150 million shares are coming! The vote is supposed to be the 15th!
Jaguar8スレ主potsy52:
Yup but unlikely will reach 8 so it will be bad for those who chase at 8. Once offering is announced, this will drop again so secure profits on your way. Take advantage of this drop
サイトムエックス セラピューティクスに関するコメント
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...
Striding towards revolutionizing cancer therapy, CytomX Therapeutics, Inc. (Nasdaq: CTMX) has announced a clinical trial collaboration and supply agreement with pharmaceutical giant Merck (known as MSD outside of the US and Canada). This collaboration is set to explore the therapeutic potential of CX-801, a novel, dually-m...
Imagine delivering a 100% revenue beat and 350% eps beat and you shed 35%, truly a work of beauty
まだコメントはありません